Radiopharmaceutical developer North American Scientific reported second-quarter revenues of $5 million, down 2% compared with the $5.1 million posted last year. For the period (end-April 30), the Chatsworth, CA-based vendor had a net loss of $4.9 million, compared with a net loss of $9,000 in the same period in 2001.
Absent one-time charges of $2.7 million associated with the write-off of costs associated with the initial composition of its Apomate technology and a $1.9 million charge for the write-down of net deferred tax assets, the company said it would have had a pro forma net loss of $225,000. President and CEO Michael Cutrer said that NAS is pleased that its core operations continue to support its ongoing R&D efforts.
By AuntMinnie.com staff writersMay 22, 2002
Related Reading
Philips, Theseus team up, February 21, 2002
NAS moves into the black, February 20, 2002
NAS revenues grow while income dips, December 11, 2001
NAS unit begins clinical Apomate trials, November 30, 2001
Copyright © 2002 AuntMinnie.com
